Paul Surdez - Catalent Vice Relations
| CTLT Stock | USD 60.75 0.25 0.41% |
Executive
Paul Surdez is Vice Relations of Catalent
| Address | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 |
| Phone | 732 537 6200 |
| Web | https://www.catalent.com |
Catalent Management Efficiency
Return On Tangible Assets is likely to gain to -0.15 in 2024. Return On Capital Employed is likely to gain to -0.08 in 2024. Total Current Liabilities is likely to drop to about 804.6 M in 2024. Liabilities And Stockholders Equity is likely to drop to about 6.6 B in 2024Catalent's management efficiency ratios could be used to measure how well Catalent manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Bjarne Tellmann | Haleon plc | 57 | |
| Donald Pearl | Bausch Health Companies | N/A | |
| Kyle Gano | Neurocrine Biosciences | 51 | |
| Jessica Perl | Emergent Biosolutions | N/A | |
| Rong MS | Amphastar P | 65 | |
| Tobias Hestler | Haleon plc | 52 | |
| MBA MPH | Amphastar P | N/A | |
| Josh Coyle | Bausch Health Companies | N/A | |
| Christina Siniscalchi | Alvotech | N/A | |
| Karen Esq | Intracellular Th | 62 | |
| Vikki Conway | Teva Pharma Industries | 52 | |
| Yoshihiro Nakagawa | Takeda Pharmaceutical Co | 64 | |
| Claire Dickson | Haleon plc | N/A | |
| Christopher OBrien | Neurocrine Biosciences | 67 | |
| Seana Carson | Bausch Health Companies | 51 | |
| Adrian Morris | Haleon plc | 57 | |
| Julie Cooke | Neurocrine Biosciences | 58 | |
| Willie MD | Intracellular Th | N/A | |
| Dov Bergwerk | Teva Pharma Industries | N/A | |
| Bjorn Timelin | Haleon plc | N/A | |
| William Hartzel | Emergent Biosolutions | N/A | |
Management Performance
| Return On Equity | -0.11 | ||||
| Return On Asset | -0.0018 |
Catalent Leadership Team
Elected by the shareholders, the Catalent's board of directors comprises two types of representatives: Catalent inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Catalent. The board's role is to monitor Catalent's management team and ensure that shareholders' interests are well served. Catalent's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Catalent's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Castellano, VP of Fin. and Investor Relations and Treasurer | ||
| Paul Surdez, Vice Relations | ||
| Joseph JD, General VP | ||
| Tom PEng, President Delivery | ||
| Trish Hunt, President Health | ||
| Peter Zippelius, Independent Director | ||
| David McErlane, Group Segment | ||
| Steven Fasman, Senior Vice President General Counsel and Corporate Secretary | ||
| Michael Hatzfeld, VP Officer | ||
| Kay Schmidt, Senior Vice President - Technical Operations | ||
| Karen Santiago, VP Office | ||
| Jonathan Arnold, President - Oral & Specialty Delivery | ||
| Ricky Hopson, Division President | ||
| John MBA, Executive Board | ||
| John Chiminski, Chairman of the Board, Chief Executive Officer | ||
| Donald Morel, Independent Director | ||
| John Greisch, Independent Director | ||
| Gregory Lucier, Independent Director | ||
| Rolf Classon, Independent Director | ||
| Michael Barber, Independent Director | ||
| Steven Esq, Corp VP | ||
| Karen Flynn, President - Biologics and Chief Commercial Officer | ||
| Michael Grippo, Senior Vice President - Strategy and Corporate Development | ||
| Matti Masanovich, Senior CFO | ||
| Julien Meissonnier, VP Officer | ||
| Christa Kreuzburg, Independent Director | ||
| Lisa Evoli, Senior Officer | ||
| Madhavan Balachandran, Independent Director | ||
| J Carroll, Independent Director | ||
| Scott Gunther, Senior Vice President - Quality & Regulatory Affairs | ||
| Wetteny Joseph, Chief Financial Officer, Senior Vice President | ||
| Alessandro Maselli, Senior Vice President - Global Operations | ||
| Dejan Lamesic, Head Development | ||
| Ricci Whitlow, President - Clinical Supply Services | ||
| Charles Lickfold, Senior Vice President, Chief Information Officer | ||
| Aristippos Gennadios, President - Softgel & Oral Technologies | ||
| Ricardo Pravda, Chief Human Resource Officer, Senior Vice President | ||
| Jack Stahl, Lead Independent Director | ||
| Z Mahdavi, Vice President of Open Innovation, Biologics, Cell and Gene Therapy | ||
| Rosemary Crane, Independent Director |
Catalent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Catalent a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.11 | ||||
| Return On Asset | -0.0018 | ||||
| Profit Margin | (0.09) % | ||||
| Operating Margin | (0.07) % | ||||
| Current Valuation | 15.68 B | ||||
| Shares Outstanding | 181.51 M | ||||
| Shares Owned By Insiders | 0.50 % | ||||
| Shares Owned By Institutions | 87.76 % | ||||
| Number Of Shares Shorted | 9.06 M | ||||
| Price To Earning | 17.80 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Catalent Stock Analysis
When running Catalent's price analysis, check to measure Catalent's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalent is operating at the current time. Most of Catalent's value examination focuses on studying past and present price action to predict the probability of Catalent's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalent's price. Additionally, you may evaluate how the addition of Catalent to your portfolios can decrease your overall portfolio volatility.